TauroLock™

TRIPLICE EFFICACIA



TAUROLOCKED LINES SAVE LIVES
20 YEARS

TauroLock™

Soluzioni antimicrobiche per il lock del catetere con **triplice efficacia** contro la minaccia di biofilm, infezioni e malfunzionamento.

1 Prevenzione ed eradicazione di **Biofilm** – in vitro ed in vivo



Rimozione del biofilm (vedi lett. 7.6)

Tutti i nostri prodotti contengono taurolidina, un agente antimicrobico che è stato studiato per decenni in numerose pubblicazioni. La taurolidina si è dimostrata efficace contro oltre 500 germi: batteri gram-positivi e gram-negativi, compresi ceppi resistenti agli antibiotici, e anche funghi (vedi lett. 7.1, accesso tramite codice QR). È stato scoperto che sradica il biofilm di vari germi (vedi lett. 7.2; 7.5 e 7.6). In un altro studio, **TauroLock™** ha inattivato vari ceppi di S. aureus (compreso MRSA) anche nel biofilm datato (vedi lett. 7.4). Questo **effetto antibiofilm** non è stato rilevato solo in studi in vitro, ma anche nei pazienti: la taurolidina si è dimostrata "**completamente sicura ed efficace**" nella rimozione di batteri e funghi come Stafilococchi, Escherichia coli, Enterobacter, Pseudomonas aeruginosa, Clostridium perfringens (vedi lett. 4.3 e 5.2).

*p≤0.05

S. aureus	P. aeruginosa	C. albicans
controllo	controllo	controllo
TauroLock™	TauroLock™	TauroLock™

2 Prevenzione delle **infezioni**

Numerosi studi clinici documentano la protezione dei CVC contro le infezioni con soluzioni lock a base di taurolidina.



Prevenzione delle CRBSI con le soluzioni **TauroLock™** in oncologia (1, 2), nutrizione parenterale (3), dialisi (4)

Comparatore Prodotto **TauroLock™**

1 **TauroLock™-HEP100** (vedi lett. 4.1)
2 **TauroLock™** (vedi lett. 4.2)
3 **TauroLock™-HEP500** (vedi lett. 6.4)
4 **TauroLock™-HEP500** (vedi lett. 3.6)

Maggiori informazioni su **taurolock.com**



Indagine di 19 anni: l'incidenza di infezioni si è ridotta da 2,36 per 1.000 giorni catetere a 0,3 per 1.000 giorni catetere (rate ratio 7,87; p<0,001). L'uso di **TauroLock™-HEP** a partire dal 2002 nei pz. con >3 inf./anno è associato alla riduzione di CRBSI (vedi lett. 6.2).



Sostituzione del CVC per infezione
Studio multicentrico osservazionale in emodialisi (vedi lett. 3.3)

- **TauroLock™-HEP500**
- Citrato ad alta concentrazione (46,7 % citrate)
- Citrato a bassa concentrazione (4 % and 30 % citrate), come riferimento

3 Prevenzione di **trombosi** ed **occlusioni**

Tutti i prodotti **TauroLock™** contengono il citrato (4 %) come anti-coagulante, raccomandato da FDA, ERBP ed altri come sicuro nel prevenire la coagulazione del sangue. In emodialisi, numerosi pazienti richiedono un maggiore effetto anticoagulante. Ecco perchè è stato sviluppato **TauroLock™-HEP500**: che mantiene ancora meglio la pervietà (vedi lett. 3.3; 3.4 e 3.7)

La combinazione di un agente antimicrobico con un anticoagulante è risultato essere più efficace (vedi lett. 2.4). Gli esperti definiscono associazione di componenti: "…i risultati più promettenti si ottengono quando i componenti antibatterici vengono integrati a lock con con citrate o eparina" (vedi lett. 2.3).

L'efficacia maggiore si ottiene con **l'aggiunta di urochinasi** trombolitica, come in **TauroLock™-U25.000**, un approccio **moderno e unico** (vedi lett. 3.1 e 3.2).



Sostituzione del CVC per malfunzionamento
Studio multicentrico osservazionale in emodialisi (vedi lett. 3.3)

- **TauroLock™-HEP500**
- Citrato ad alta concentrazione (46,7 % citrate)
- Citrato a bassa concentrazione (4 % and 30 % citrate), come riferimento

La formazione del biofilm e la coagulazione del sangue dovrebbero essere prevenute fin dall'inizio a causa del rischio di: infiammazione silente, trombosi, infezione del flusso ematico, insuccesso del trattamento antibiotico o persino resistenza agli antibiotici e sostituzioni del catetere a causa di infezione o malfunzionamento.

Prevenire è meglio che curare!

TauroLock™

4. Sicurezza

TauroLock™, **TauroLock™-HEP100**, **TauroLock™-HEP500** e **NutriLock™** sono approvate per l'uso dalla nascita in avanti, neonati inclusi (per i dati clinici vedere lett. 4.1; 5.1; 5.2 e 6.3). Per maggiori dettagli riferirsi alle IFU.

I prodotti **TauroLock™** hanno dimostrato di migliorare anche il quadro infiammatorio dei pazienti (vedere lett. 3.6; 3.7 e 3.8).

5. Risparmio sui costi

I prodotti **TauroLock™** non proteggono i pazienti solo dalle complicanze. Riducono anche i costi associati al catetere rispetto alle alter soluzioni lock.



Costi associati al catetere inclusa la soluzione lock
Il comparatore dei lock è impostato al 100 %

Bibliografia

LINEE GUIDA

Position statement of European Renal Best Practice (ERBP) 2010
"B.3.1 The preventive use of antimicrobial locks is advocated to reduce the rate of CRBSI…
The 46.7 and 30% [citrate] concentration ranges have been considered unsafe. For that reason, the low 4% concentration might be preferred, as also proposed by the American Society of Diagnostic and Interventional Nephrology (ASDIN)."

Guideline of the German Society of Nephrology 2019
"…Blocking with antibacterial lock solutions may be part of measures against overly high bloodstream infections in catheter patients (Cat. IB)…taurolidine and gentamicin exert only antimicrobial effectiveness…
…An additional option is the intermittent (once weekly) use of urokinase in the lock solution (Cat IB)…."

Australian guidelines for haemodialysis catheters 2015
"Taurolidine has been found to:
- have a very broad-spectrum antimicrobial activity.
- decrease development of biofilms.
- be associated with a reduced CRBSI rate compared to heparin."

GAVeCeLT consensus 2016
"…the drugs most likely to be used as antibacterial lock are taurolidine and citrate, which have optimal characteristics in terms of safety, efficacy and cost effectiveness."

INS 2024
"61.B.8.d.i. Taurolidine was effective in prevention of catheter-related bloodstream infections (CR-BSIs) for patients on HPN… (I)"

ESPEN guideline on home parenteral nutrition 2020
"Recommendation 34: As an additional strategy to prevent CRBSIs, taurolidine locking should be used because of its favorable safety and cost profile. Grade of Recommendation B - Strong consensus (100% agreement)"

Fabbricante

TauroPharm GmbH
August-Bebel-Straße 51
D-97297 Waldbüttelbrunn

Tel. +49 931 30 42 99 0
Fax +49 931 30 42 99 29

Distributore

85300IT/18/24

Publications on safety and efficacy

1. GUIDELINES AND RECOMMENDATIONS

1.1. Infusion Therapy Standards of Practice 2024
Nickel et al. *J Infus Nurs 2024.* DOI: 10.1097/NAN.0000000000000532

1.2. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP)
Vanholder et al. *NDT Plus* 2010. DOI: 10.1093/ndtplus/sfq041

1.3. Guideline for infection prevention and hygiene 2019 in addition to the German dialysis standard
German Society of Nephrology (Deutsche Gesellschaft für Nephrologie, DGfN) 2019. Print.

1.4. Australian guidelines for haemodialysis catheters
National Health and Medical Research Council (NHMRC) 2015. Print.

1.5. FDA issues warning on tricitrasol dialysis catheter anticoagulant
Food and Drug Administration, U.S. Department of Health and Human Services. 2000. Print.

1.6. Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus
Pittiruti et al. *J Vasc Access 2016.* DOI: 10.5301/jva.5000576

1.7. ESPEN guideline on home parenteral nutrition
Pironi et al. *Clin Nutr* 2020. DOI: 10.1016/j.clnu.2020.03.005

1.8. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Venous access
Kolaček et al. / ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. *Clin Nutr* 2018. DOI: 10.1016/j.clnu.2018.06.952

1.9. Prevention of infections related to central-venous catheters – for patients, adults and children, receiving short- or long-term parenteral nutrition (SFNCM)
Schneider et al. *French Society for Clinical Nutrition and Metabolism (SFNCM)* 2019. Print.

2. META-ANALYSES, REVIEW, SURVEY

2.1. Meta-analysis of the efficacy of taurolidine in reducing catheter-related bloodstream infections for patients receiving parenteral nutrition
Vernon-Roberts et al. *J Parenter Enteral Nutr* 2022. DOI: 10.1002/jpen.2363

2.2. A multi-national survey of experience and attitudes towards managing catheter related blood stream infections for home parenteral nutrition
Joly et al. *Clin Nutr ESPEN* 2023 doi: 10.1016/j.clnesp.2023.06.032.

2.3. Any use for alternative lock solutions in the prevention of catheter-related blood stream infections?
Labriola et al. *J Vasc Access* 2017 Mar 6;18(Suppl. 1):34-38. DOI: 10.5301/jva.5000681.

2.4. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials
Zhao et al. *Am J Kidney Dis* 2014. DOI: 10.1053/j.ajkd.2013.08.016

3. CLINICAL STUDIES: DIALYSIS

3.1. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study
Al Ali et al. *Nephrol Dial Transplant* 2018. DOI: 10.1093/ndt/gfx187

3.2. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters
Winnicki et al. *Kidney Int* 2018. DOI: 10.1016/j.kint.2017.06.026

3.3. The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients
Van Roeden et al. *BMC Nephrology* 2021. DOI: 10.1186/s12882-021-02519-3

3.4. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis
Solomon et al. *Semin Dial* 2012. DOI: 10.1111/j.1525-139X.2011.00951.x

3.5. A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients
Taylor et al. *J Ren Care* 2008. DOI: 10.1111/j.1755-6686.2008.00027.x

3.6. Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients
Fontseré et al. *Antimicrob Agents Chemother* 2014. DOI: 10.1128/AAC.02421-14

3.7. Effect of taurolidine citrate and unfractionated heparin on inflammatory state and dialysis adequacy in hemodialysis patients
Ezzat et al. *J Vasc Access* 2023. DOI: 10.1177/11297298211023295

3.8. Patients on HD with central catheters locked with taurolidine have a similar inflammatory profile to subjects with native arteriovenous fistula
Navarro-González et al. *Nephrol Dial Transplant* 2023. DOI:10.1093/ndt/gfad063b_3195

4. CLINICAL STUDIES: ONCOLOGY/HAEMATOLOGY

4.1. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin
Handrup et al. *Pediatr Blood Cancer* 2013. DOI: 10.1002/pbc.24482

4.2. Taurolidine-Citrate Line Locks Prevent Recurrent Central Line-Associated Bloodstream Infection in Pediatric Patients
Clark et al. *Pediatr Infect Dis J* 2019. DOI: 10.1097/INF.0000000000002191

4.3. Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients
Brescia et al. *J Vasc Access* 2023. DOI: 10.1177/11297298211026453

5. CLINICAL STUDIES: INTENSIVE CARE

5.1. Effects of prophylactic use of taurolidine-citrate lock on the number of catheter-related infections in children under 2 years of age undergoing surgery
Łyszkowska et al. *J Hosp Infect* 2019. DOI: 10.1016/j.jhin.2019.04.022

5.2. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study
Savarese et al. *J Hops Infec*t 2024. DOI: 10.1016/j.jhin.2023.11.003

6. CLINICAL STUDIES: PARENTERAL NUTRITION

6.1. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial
Tribler et al. *Am J Clin Nutr* 2017. DOI: 10.3945/ajcn.117.158964

6.2. The incidence and management of complications of venous access in home parenteral nutrition (HPN): A 19 year longitudinal cohort series
Leiberman et al. *Clin Nutr ESPEN* 2020. DOI: 10.1016/j.clnesp.2020.03.025

6.3. Strategies to Reduce Catheter-Related Bloodstream Infections in Pediatric Patients Receiving Home Parenteral Nutrition: The Efficacy of Taurolidine-Citrate Prophylactic-Locking
Lambe et al. *Parenter Enteral Nutr* 2018. DOI: 10.1002/jpen.1043.

6.4. Cost-effectiveness of taurolidine locks to prevent recurrent catheter-related blood stream infections in adult patients receiving home parenteral nutrition: a 2-year mirror-image study
Lannoy et al. *Clin Nutr* 2021. DOI: 10.1016/j.clnu.2021.01.017

7. STUDIES: IN VITRO AND BIOFILM

7.1. Activities of taurolidine in vitro and in experimental enterococcal endocarditis
Torres-Viera et al. *Antimicrob Agents Chemother* 2000. DOI: 10.1128/AAC.44.6.1720-1724.2000

7.2. Antimicrobial activity of a novel catheter lock solution
Shah et al. *Antimicrob Agents Chemother* 2002. DOI: 10.1128/AAC.46.6.1674-1679.2002

7.3. Microbiocidal effects of various taurolidine containing catheter lock solutions
Olthof et al. *Clin Nutr.* 2015. DOI: 10.1016/j.clnu.2014.04.023

7.4. In Vitro Approach for Identification of the Most Effective Agents for Antimicrobial Lock Therapy in the Treatment of Intravascular Catheter-Related Infections Caused by Staphylococcus aureus
Hogan et al. *Antimicrob Agents Chemother* 2016. DOI: 10.1128/AAC.02885-15

7.5. Antimicrobial activity of hemodialysis catheter lock solutions in relation to other compounds with antiseptic properties
Pjątkowska et al. *PLoS ONE* 2021. DOI: 10.1371/journal pone.0258148

7.6. In vitro comparison of the effectiveness of various antimicrobial locks with taurolidine in the treatment and prevention of catheter-related bloodstream infections in patients receiving parenteral nutrition
Víšek et al. *Nutrition* 2023. DOI: 10.1016/j.nut.2023.112115

85300EN-L/18/24